In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Growth

Set Alert for Growth

New Science As A Business Growth Strategy

Finding innovative ways to adapt the biopharma business model to external and internal challenges is a key competitive differentiator for today’s C-suite leadership. 

Business Strategies Growth Research and Development Strategies
Advertisement

Latest From Growth

PureTech’s Problem-Solving Skills Target The BIG Picture

PureTech Health has amassed niche expertise and built a unique structure that allows it to develop technologies for unmet needs, in the separate but related areas of brain-immune-gut. And now, with the experienced ex-Sanofi CEO Chris Viehbacher as interim chair, PureTech can target a smooth path to its next growth stages in the “BIG Axis.” Senior executives Eric Elenko and Joep Muijrers reveal more about the focus and aims of the Boston, US group.

C-Suite Speaks Business Strategies

MorphoSys: A European Champion Crossing The Biopharma Rubicon

The Munich-based company is one of a handful of mature European biotechs poised to enter the big league. New CEO Jean-Paul Kress talks to In Vivo about the firm’s next generation antibody platform and why US expansion is crucial to its future.

BioPharmaceutical C-Suite Speaks

The Case For Agile Innovation In Health Care

In a recent Bain & Company survey, nearly 80% of health care executives said they needed to be more agile. Yet more than half said they were not familiar with formal agile methodologies and tools, and were not using them in their companies.

Growth Commercial

European Companies Are Now Being ‘Properly Funded’

In the first half of 2019, life science companies raised $469m through series A rounds in Europe – a solid start to the year compared to the $686m companies raised in 2018 overall. Silicon Valley Bank expects the European sector to be in “rude health” for the next two to three years at least, when it comes to accessing VC cash.

Business Strategies Commercial

MedTech Forum 2019: Consumers And Wellness, Or Patients And Health Care?

As health care transitions to digitally enabled wellness, medtechs will be missing a trick if they persist in holding onto the delivery, business methods and models that were the standard of the early 2000s. Heightened expectations of the new options for dealing with personal health mean that new opportunities are there for the taking – but industry shouldn’t let the tech companies have it all their own way, advised ZS principal Brian Chapman.

Digital Health Human Capital

Building The Biotech City: Is Los Angeles The Go-To Destination For Tomorrow’s Drug Innovations?

The complexity of producing viable drug candidates is increasing as an abundance of new science keeps extending the range of possible targets and fragmenting disease subtypes. Proximity to novel exploratory research is a driver of pipeline productivity – so can physical location within a communal geography of well-resourced intellectual firepower raise the odds for R&D success? In Vivo sits down with eight key leaders in academia, VC, commercial real estate and groundbreaking biotech to discuss how Los Angeles – the “out there” city of out-sized ambitions – is positioning itself for global leadership in the curative technologies of the future.

US States Growth
See All
UsernamePublicRestriction

Register

Advertisement